A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 Mcg Once-daily in Combination With GW642444 25 Mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Japanese Subjects With Chronic Obstructive Pulmonary Disease.

Trial Profile

A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 Mcg Once-daily in Combination With GW642444 25 Mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Japanese Subjects With Chronic Obstructive Pulmonary Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2015

At a glance

  • Drugs Umeclidinium/vilanterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 07 Jul 2014 According to a GlaxoSmithKline media release, Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Anoro-Ellipta (umeclidinium/vilanterol) for the relief of various symptoms due to airway obstruction with COPD.
    • 13 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 19 Aug 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top